Edwards Lifesciences expects to launch a new bioprosthetic valve next year. Management has already described its Inspiris as a "game changer" that could be useful for a younger patient population.
Axion Biosystems has raised $6 million to back its Maestro multiwell microelectrode array platform, a high-throughput system for cellular analysis that enables researchers to recreate complex, active systems such as brain activity and heartbeats.
Mitralign has raised $39.8 million in a Series E round to help it get U.S. and EU approvals for its tricuspid valve repair system and to launch its mitral valve repair system in Europe. Transcatheter mitral valve repair and replacement were white-hot areas of strategic investment last year as major med techs worked to anticipate the best follow-up play to the massive success of transcatheter aortic valve replacement.
Early evidence suggests that Novocure's Tumor Treating Fields technology may be useful in combination with a newer class of anti-cancer drugs, PD-1 inhibitors.
Bioengineered blood vessels could see an early use aiding hemodialysis patients who have exhausted their vascular access options.
Several tests exist to detect atherosclerosis, the plaque buildup in arteries that can lead to heart attack and stroke, but each has its limitations. NIH-supported labs at UC Irvine and the University of Southern California have combined two types of imaging to create a promising new method to identify atherosclerotic plaques.
Interventional oncology specialist BTG is working to make med tech more relevant in oncology--something it's got a shot at doing as localized treatment delivery and minimally invasive surgical techniques continue to emerge.
AliveCor brought on a former Google exec last year to run the company. Now, it may be on the path to the data it needs to make its smartphone-based ECG recorder the standard-of-care for patients with undiagnosed heart palpitations.
The first U.S. regulatory test for a drug that incorporates medication adherence technology has been met with a rejection. The Food and Drug Administration issued a complete response letter to Otsuka Pharmaceutical and Proteus Digital Health for their drug/device combination of Abilify with Proteus' ingestible sensor.
Two years ago, Medtronic rolled out its Reveal Linq, a tiny implantable cardiac monitor, with annual sales predictions to the tune of $1 billion to $2 billion. Now, the company is reporting one-year data from a real-world study of the device showing that it was better at detecting atrial fibrillation than previously thought.